Relevance of stromal interaction molecule 1 (STIM1) in experimental and human stroke.
Rosita StanzioneMaurizio ForteMaria CotugnoFranca BianchiSimona MarchittiSperanza RubattuPublished in: Pflugers Archiv : European journal of physiology (2021)
Stroke represents a main cause of death and permanent disability worldwide. In the attempt to develop targeted preventive and therapeutic strategies, several efforts were performed over the last decades to identify the specific molecular abnormalities preceding cerebral ischemia and neuronal death. In this regard, mitochondrial dysfunction, autophagy, and intracellular calcium homeostasis appear important contributors to stroke development, as underscored by recent pre-clinical evidence. Intracellular calcium (Ca2+) homeostasis is regulated, among other mechanisms, by the calcium sensor stromal interaction molecule 1 (STIM1) and calcium release-activated calcium modulator (ORAI) members, which mediate the store-operated Ca2+ entry (SOCE). The activity of SOCE is deregulated in animal models of ischemic stroke, leading to ischemic injury exacerbation. We found a different pattern of expression of few SOCE components, dependent from a STIM1 mutation, in cerebral endothelial cells isolated from the stroke-prone spontaneously hypertensive rat (SHRSP), compared to the stroke-resistant (SHRSR) strain, suggesting a potential involvement of this mechanism into the stroke predisposition of SHRSP. In this article, we discuss the relevant role of STIM1 in experimental stroke, as highlighted by the current literature and by our recent experimental findings, and the available evidence in the human disease. We also provide a glance on future perspectives and clinical implications of STIM1.
Keyphrases
- cerebral ischemia
- atrial fibrillation
- endothelial cells
- subarachnoid hemorrhage
- blood brain barrier
- brain injury
- bone marrow
- oxidative stress
- cell death
- chronic obstructive pulmonary disease
- systematic review
- signaling pathway
- intensive care unit
- risk assessment
- transcription factor
- cancer therapy
- multiple sclerosis
- induced pluripotent stem cells
- protein kinase
- quality improvement
- poor prognosis
- human health